These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9191151)

  • 21. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
    Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
    Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy for inherited immunodeficiencies.
    Howe S; Thrasher AJ
    Curr Hematol Rep; 2003 Jul; 2(4):328-34. PubMed ID: 12901330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Substitution therapy with hematopoietic progenitors in the primary immunodeficiencies].
    Español T
    Allergol Immunopathol (Madr); 2001; 29(3):118-21. PubMed ID: 11434885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Transplantation of T cell-depleted marrow from parents in a case of severe combined immunodeficiency with adenosine deaminase deficiency].
    Yamagami M; Matsuda A; Nakarai T; Katayama K; Saigawa Y; Horita S; Miura M; Kato E; Koizumi S; Taniguchi N
    Rinsho Ketsueki; 1987 Sep; 28(9):1669-74. PubMed ID: 3325660
    [No Abstract]   [Full Text] [Related]  

  • 25. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
    Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
    Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospects for gene therapy for immunodeficiency diseases.
    Kantoff PW; Freeman SM; Anderson WF
    Annu Rev Immunol; 1988; 6():581-94. PubMed ID: 3289578
    [No Abstract]   [Full Text] [Related]  

  • 27. [Adenosine deaminase deficiency].
    Sakiyama Y
    Ryoikibetsu Shokogun Shirizu; 2000; (32):32-4. PubMed ID: 11212730
    [No Abstract]   [Full Text] [Related]  

  • 28. Lentiviral vectors for the treatment of primary immunodeficiencies.
    Farinelli G; Capo V; Scaramuzza S; Aiuti A
    J Inherit Metab Dis; 2014 Jul; 37(4):525-33. PubMed ID: 24619149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for immunodeficiency.
    Candotti F
    Curr Allergy Asthma Rep; 2001 Sep; 1(5):407-15. PubMed ID: 11892066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in genetic therapy for severe combined immunodeficiency associated with adenosine deaminase deficiency.
    Williams DA
    Mol Ther; 2009 Apr; 17(4):577-8. PubMed ID: 19337228
    [No Abstract]   [Full Text] [Related]  

  • 31. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
    Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
    Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
    [No Abstract]   [Full Text] [Related]  

  • 32. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.
    Kohn DB; Weinberg KI; Nolta JA; Heiss LN; Lenarsky C; Crooks GM; Hanley ME; Annett G; Brooks JS; el-Khoureiy A
    Nat Med; 1995 Oct; 1(10):1017-23. PubMed ID: 7489356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical and immunological status following gene therapy and PEG-ADA therapy for adenosine deaminase (ADA) deficiency.
    Fairbanks LD; Simmonds HA; Hoogerbrugge PM; van Beusechem VW; Valerio D; Moseley A; Levinsky RJ; Gaspar HB; Morgan G
    Adv Exp Med Biol; 1994; 370():391-4. PubMed ID: 7660936
    [No Abstract]   [Full Text] [Related]  

  • 34. Gene therapy's out-of-body experience.
    Scott CT; DeFrancesco L
    Nat Biotechnol; 2016 Jun; 34(6):600-7. PubMed ID: 27281416
    [No Abstract]   [Full Text] [Related]  

  • 35. Lymphoma in a patient with severe combined immunodeficiency with adenosine deaminase deficiency, following unsustained engraftment of histoincompatible T cell-depleted bone marrow.
    Kapoor N; Jung LK; Engelhard D; Filler J; Shalit I; Landreth KS; Good RA
    J Pediatr; 1986 Mar; 108(3):435-8. PubMed ID: 3512811
    [No Abstract]   [Full Text] [Related]  

  • 36. [Current status and future prospects of stem cell gene therapy for primary immunodeficiency].
    Uchiyama T; Onodera M
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(3):148-55. PubMed ID: 23812072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the status of gene therapy for primary immunodeficiency?
    Blaese RM
    Immunol Res; 2007; 38(1-3):274-84. PubMed ID: 17917032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives of gene therapy for primary immunodeficiencies.
    Chinen J; Puck JM
    Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):523-7. PubMed ID: 15640693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for ADA-SCID, the first marketing approval of an
    Aiuti A; Roncarolo MG; Naldini L
    EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy for primary adaptive immune deficiencies.
    Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
    J Allergy Clin Immunol; 2011 Jun; 127(6):1356-9. PubMed ID: 21624615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.